From: Application of a composite measure of product adherence, protocol compliance, and semen exposure to a phase III microbicide HIV prevention trial
All applicators (n = 901)
Group
Number of applicators
Number of applicators with detectable TFV
1% TFV Gel
556
539 (97%)
Placebo
345
19 (5%)
Vaginally inserted 1% TFV gel
456
452 (99%)